TYK-00540 tablets for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be advanced or metastatic and standard treatments no longer work, are not tolerated, or are refused.
- You need to have tumors that can be measured on scans or evaluated by a doctor.
- You must be well enough to perform daily activities (ECOG score 0 or 1).
- Your organ functions (liver, kidneys, heart, blood) must be within certain limits.
- For some study groups, you may need to have a specific type of cancer, such as ovarian or breast cancer, with certain treatment history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, TYK-01054, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or control the cancer.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
This trial is testing a new tablet called YY2201 for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help shrink or control the tumor.
This trial tests a new drug called SYH2095 for people with advanced solid tumors, including a specific type of breast cancer (HR+/HER2-). The goal is to see if it is safe and effective. You may join if you are an adult with a tumor that can be measured and you are in generally good health.
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
Hear when a new HR-positive, HER2-negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.